Intravenous Iron Sucrose for Children With Iron Deficiency Anemia

Kaneva, Kristiyana; Chow, Erika; Rosenfield, Cathy G.; Kelly, Michael J.

doi:10.1097/mph.0000000000000879

Cited by 24 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…documented. A rise in posttreatment hemoglobin levels implies that erythropoietic recovery is achieved with intravenous iron sucrose which also 16,18 strengthens the findings of our study. The most common side effect in our study is fever 10% whereas the study by Mantadakis et al reported the most common adverse effect of parental iron to be injection site extravasation followed by a 19 transient alteration in taste.…”

Section: Table II :Feeding History and Diagnosis At The Time Of Admis...supporting

confidence: 88%

Parental Iron Therapy to Treat Iron Deficiency Anemia in Malnourished Children

Khan¹,

Ma²,

Abbas³

et al. 2022

JIIMC

View full text Add to dashboard Cite

Objective: To evaluate the safety and efficacy of parental iron therapy to treat iron deficiency anemia in malnourished children. Study Design: Quasi experimental design. Place and Duration of Study: Stabilization Centre, Children Hospital and the Institute of Child Health, Multan from 1 December 2014 to 31 December 2020. Materials and Methods: A total of 250 malnourished children with iron deficiency were included in the study. The laboratory parameters i.e., Hemoglobin, Hematocrit, Red Blood Cells Count, mean corpuscular hemoglobin, mean corpuscular volume, and Serum ferritin of all patients were done. Using the iron deficit formula, all participants were given the measured iron sucrose complex. The iron sucrose complex was diluted with 0.9% normal saline and administered steadily for 3-4 hours. After 6 weeks of therapy, hemoglobin, RBC count , ferritin was measured. Comparison of mean ±SD of baseline laboratory parameters and after 6 weeks of iron supplementation was analyzed by using t-test. Results: A total of 250 participants were registered, male patients (57.2%) were more than female patients (42.8 %). Most of the 92(36.8%) participants were 12-24 months old. The key cause of anemia among 102(40.8%) admitted patients was inadequate diet or excessive milk consumption. The mean ±SD value of the Hb level at admission was 7.5±1.9 and it increased to 11±1.15g/dL after 6 weeks of active supplementation which is statistically significant (P-value < 0.05). Six weeks after giving intravenous iron therapy mean serum Ferritin increased from 11.5ml to 21.61 ng/ml. Conclusion: Current study concluded that controlled administration of IV iron sucrose for treatment of iron deficiency anemia among inpatients is efficacious and safe. IV iron sucrose should be considered for patient with severe IDA, those who are not compliant with oral formulations, and patients with malabsorption.

show abstract

Section: Table II :Feeding History and Diagnosis At The Time Of Admis...supporting

confidence: 88%

Parental Iron Therapy to Treat Iron Deficiency Anemia in Malnourished Children

Khan¹,

Ma²,

Abbas³

et al. 2022

JIIMC

View full text Add to dashboard Cite

show abstract

“…The majority of IV iron sucrose infusions were administered to patients with IBD, and it was reported that the treatment was safe and tolerable. [5][6][7]17,18 A small number of children experienced coughing, wheezing, or side effects that were not life-threatening and did not require hospitalization. 5,17 Mantadakis et al 19 reported mild side effects such as phlebitis at the infusion site.…”

Section: Discussionmentioning

confidence: 99%

Intravenous Iron Therapy for Children With Iron Deficiency Anemia

Orhan¹,

Büyükavcı²

2022

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Iron deficiency anemia in children is a public health problem. Although oral iron treatment is the first choice, common side effects and compliance problems can cause the treatment to be interrupted. This study retrospectively evaluated children treated with intravenous (IV) iron sucrose or ferric carboxymaltose (FCM) and compared the treatment processes and efficacy. The demographic characteristics and treatment details of the 44 children with iron deficiency anemia were retrospectively evaluated. Iron sucrose was administered to 25 patients and FCM was administered to 19 patients. The IV iron infusion was applied to 64% of the patients because of unresponsiveness to oral treatment, 25% of the patients because of compliance problems, and 11% of the patients because of severe anemia. IV iron therapy increased hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, red-cell distribution width, and serum ferritin levels and decreased platelet count. The mean number of infusions per patient in the FCM group was lower, and the total treatment time was shorter. In conclusion, IV iron sucrose or FCM can be used in children with nonadherence to oral therapy and severe anemia in addition to specific indications.

show abstract

“…Despite these limitations, our study supports previously published data describing the use of IV iron sucrose in children. 9,11,12…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of intravenous iron sucrose in children younger than 2 years with intestinal failure

2022

View full text Add to dashboard Cite

Iron‐deficiency anemia (IDA) is highly prevalent in children with intestinal failure (IF) and oral iron supplementation is often ineffective in this patient population. Even though various intravenous (IV) iron formulations are available, there is a dearth of data on the use of newer parenteral iron products such as IV iron sucrose, especially in infants and young children (<2 years of age) with IF. To determine safety and efficacy, we performed a retrospective chart review on infants and children younger than 2 years with IF who received IV iron sucrose for IDA between October 2019 and August 2021. The review revealed that 10 events of IV iron sucrose replacement were administered to five children aged 4–22 months with IF and IDA. We observed a mean increase in hemoglobin of 1.9 ± 0.6 g/dl, and peak hemoglobin levels were seen at 4.3 ± 0.8 weeks after the IV iron sucrose dose. The infusions were well tolerated, and no short‐term adverse reactions or laboratory abnormalities were observed. Based on these observations, the use of IV iron sucrose appears to be safe and effective in infants and young children with IF and could be considered in the management of IDA in this patient population.

show abstract

Intravenous Iron Sucrose for Children With Iron Deficiency Anemia

Cited by 24 publications

References 14 publications

Parental Iron Therapy to Treat Iron Deficiency Anemia in Malnourished Children

Parental Iron Therapy to Treat Iron Deficiency Anemia in Malnourished Children

Intravenous Iron Therapy for Children With Iron Deficiency Anemia

Efficacy and safety of intravenous iron sucrose in children younger than 2 years with intestinal failure

Contact Info

Product

Resources

About